U.S. Markets closed

Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data

·1 min read
  • Acadia Pharmaceuticals Inc (NASDAQ: ACADstopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller.

  • The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients.

  • Initial data announced in April showed that the primary endpoint of pain intensity was not met.

  • Rival Vertex boasted a mid-phase win for a similar candidate.

  • Acadia has also discontinued ACP-319, which was tested in combination with Calquence in a phase 1 trial in relapsed/refractory chronic lymphocytic leukemia.

  • In Acadia's earnings report, the company hopes that trofinetide, submitted last month to the FDA for approval, will become the first treatment for a rare neurological condition called Rett syndrome.

  • It also pointed to an in-house molecule called ACP-204, which is in phase 1 trials for neuropsychiatric indications. Acadia aims for ACP-204 to build upon its learnings garnered from the neuropsychiatric drug Nuplazid, the company's only approved therapy to date.

  • Price Action: ACAD shares are down 3.76% at $16.00 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.